JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
On Thursday, TD Cowen reiterated its Buy rating on CIGNA Corporation (NYSE:CI) with a consistent price target of $380.00. The firm’s analyst highlighted the positive impact of the recent sale of CIGNA’s government business to Health Care Service Corporation (HCSC) on the company’s strategic direction. With a market capitalization of $88.25 billion and an impressive YTD return of 16.9%, InvestingPro analysis indicates CIGNA is currently trading below its Fair Value, suggesting potential upside opportunity.
The analyst pointed out that the divestiture allows CIGNA to concentrate more on its Health Care services, moving away from being viewed solely as a managed care organization (MCO). The focus is now on growth areas such as specialty services and the adoption of biosimilars. The shift is expected to potentially re-rate CIGNA’s multiple back to the 12-13x range, with the added benefit of potential clarity on Pharmacy Benefit Manager (PBM) reform in 2025, which could remove another concern for investors. The company’s strong financial health is reflected in its "GREAT" overall score from InvestingPro, which evaluates multiple financial metrics including profitability and growth potential.
CIGNA’s recent sale of its Medicare and Part D business is seen as a strategic move that will enable the company to redirect attention towards its Evernorth segment. This segment stands to gain from the growth in specialty services and biosimilars. Despite the near-term focus on stop-loss insurance, TD Cowen suggests that CIGNA’s position is favorable due to its lack of exposure to Medicare Advantage (MA) and Medicaid (MDCD), shielding it from government-related market fluctuations and policy changes.
The analyst also noted that being free from the annual Medicare Advantage cycle’s volatility, which includes rate notices, star ratings, and the need for competitive investments, is a positive for CIGNA. This independence from government-related sentiment headwinds, such as potential Medicaid cuts or changes due to the Inflation Reduction Act and other policy adjustments, provides a more stable outlook for the company.
In summary, TD Cowen’s analysis supports a Buy rating for CIGNA stock, with the firm’s favorable view bolstered by the recent business sale and the company’s strategic pivot towards high-growth healthcare services. The reiterated $380.00 price target reflects the firm’s confidence in CIGNA’s future performance. The company’s solid fundamentals are further evidenced by its impressive revenue of $247.12 billion and a notable dividend growth of 22.76% over the last twelve months. For deeper insights into CIGNA’s valuation and growth prospects, investors can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports.
In other recent news, Cigna Corporation has made notable announcements that could impact investor perspectives. The company reaffirmed its financial goals for 2025, projecting a consolidated adjusted income from operations of at least $29.50 per share. This includes a minimum of $7.2 billion in pre-tax adjusted income from operations for Evernorth and at least $4.1 billion for Cigna Healthcare. Additionally, Cigna announced significant leadership changes, with Brian Evanko appointed as President and Chief Operating Officer and Ann Dennison as Executive Vice President and Chief Financial Officer.
Cantor Fitzgerald raised its price target for Cigna’s stock to $365, maintaining an Overweight rating, reflecting optimism about the company’s strategic initiatives and growth potential. Meanwhile, Bernstein maintained a Market Perform rating with a $323 price target, expressing confidence in Evanko’s leadership capabilities. The healthcare sector, including Cigna, experienced a downturn amid a Department of Justice investigation into Medicare billing practices, though no direct accusations were made against Cigna. However, the sector saw a slight recovery following President Trump’s supportive comments on social security and Medicare, with Cigna’s stock experiencing a modest rise. These developments highlight a dynamic period for Cigna and the broader healthcare industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.